Form 10-Q Mersana Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Paradium AI (PAAI) Halted, News Pending
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Citi Starts Mersana (MRSN) at Buy
November 15, 2024 4:52 AM ESTCiti analyst Yigal Nochomovitz initiates coverage on Mersana (NASDAQ: MRSN) with a Buy rating and a price target of $5.00.
The analyst comments "
MRSN expects to share initial data from the XMT-1660 (B7-H4 ADC) Ph1 by YE24. We see this readout as a... More
